We recognize that factors such as pre-existing medical conditions (e.g., hypertension), long-term immunosuppressive medication use, and specific aspects of TTP itself—like ADAMTS13 activity and antibody status—could have impacted brain volume measurements. This evidence concerns the gene ADAMTS13 and hypertensive disorder.